Menu
The drug industry and 340B program advocates offered mixed reactions Monday to a key senator’s latest inquiries into drugmakers’ contract pharmacy restrictions as part of an ongoing congressional probe of the drug pricing program.

Sen. Cassidy’s Letters to Drug Manufacturers Welcomed by Drug Industry Trade Group, Draw Skepticism from 340B Provider Advocates

Bella Czajkowski and Shannon Young, National Correspondent 340B Report Views
The drug industry and 340B program advocates offered mixed reactions Monday to a key senator’s latest inquiries into drugmakers’ contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

CMS Publishes Final Rule on Medicaid Rebates with Significant 340B Implications

Norma Carrizales, Senior Account Manager, Cervey

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live